Rapid Review Quiz: Vitamin D

Romesh Khardori, MD


September 06, 2022

The double-blind, randomized, placebo-controlled trial included 1256 participants with impaired glucose tolerance. Participants were randomly assigned to receive eldecalcitol or placebo for 3 years. No overall difference was found between patients taking eldecalcitol and the placebo group in the rates of regression to normoglycemia or incidence of type 2 diabetes. However, after adjustment for prespecified covariables, eldecalcitol was effective in preventing the development of type 2 diabetes among those with the lowest divisions of homeostatic model assessment (HOMA), HOMA-insulin resistance, and fasting immunoreactive insulin. The researchers concluded that vitamin D supplementation benefitted insufficient basal insulin secretion. Differences in rates and types of adverse events between the two groups were insignificant.

Learn more about vitamin D supplementation.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.